Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

AGNES - Aging Nephropathy Study, a Prospective Observational Cohort of Chronic Kidney Disease in Elderly Patients

Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
Линкът е запазен в клипборда
СъстояниеНабиране
Спонсори
University of Sao Paulo General Hospital

Ключови думи

Резюме

With aging population, a high prevalence of obesity, systemic arterial hypertension and diabetes mellitus, we are facing an increased incidence of elderly patients with chronic kidney disease (CKD) initiating renal replacement therapy. The correct diagnosis of CKD, the prognosis of the elderly patient with CKD, mainly comparing initiate dialysis vs. remain in conservative treatment, the nutritional prognostic markers (sarcopenia), cardiovascular, mineral and bone metabolism, geriatric syndromes and sleep disorders are still debatable. Elderly patients are usually excluded from clinical trials and the scientific evidence is either scarce or based on retrospective data. Thus, the present study is a prospective cohort to evaluate the long-term evolution of patients ≥ 70 years with stage 4 or 5 CKD. The main outcomes are mortality and dialysis. These endpoints will be correlated with: geriatric syndromes, markers of mineral and bone metabolism (calcium, phosphorus, Klotho, parathormone,fibroblast growth factor 23, fibroblast growth factor 21, 25(OH) vitamin D and 1,25 vitamin D), cognitive decline, clinical demographic and biochemical data, bone densitometry and echocardiography, and sleep data. Patients will be follow-up at the nephrology outpatient clinic of the Hospital das Clinicas, Universidade de Sao Paulo. The sample size was calculated to be 500 subjects. The summary methodology will include: broad geriatric assessment, cognition test, fragility, Charlson comorbidity scores, biochemical measurements of urea, creatinine, alkaline phosphatase, parathyroid hormone, calcium, phosphorus, vitamin D, vitamin B12, folic acid, thyroid hormones, hepatitis virus, serum albumin, albumin/creatinine ratio, protein/creatinine ratio, 24-h urinary protein, skull tomography, bone densitometry, ambulatory blood pressure monitoring, actigraphy, polysomnography, Epworth Sleepiness Scale, Pitssburgh questionnaire and segmental electric bioimpedance

Дати

Последна проверка: 09/30/2019
Първо изпратено: 10/06/2019
Очаквано записване подадено: 10/15/2019
Първо публикувано: 10/17/2019
Изпратена последна актуализация: 10/15/2019
Последна актуализация публикувана: 10/17/2019
Действителна начална дата на проучването: 08/31/2019
Приблизителна дата на първично завършване: 09/29/2022
Очаквана дата на завършване на проучването: 12/29/2022

Състояние или заболяване

Chronic Kidney Diseases
Elderly
Mortality
Renal Replacement Therapy

Фаза

-

Критерии за допустимост

Възрасти, отговарящи на условията за проучване 70 Years Да се 70 Years
Полове, допустими за проучванеAll
Метод за вземане на пробиNon-Probability Sample
Приема здрави доброволциДа
Критерии

- Clinical diagnosis of Chronic Kidney Disease stage 4 or 5

- Minimal age of 70 years

- Must be able to understand and sign the consent form

Exclusion Criteria:

- Patients who did not accept and sign the consent form

- Patients with cancer and life expectance lower than 6 months

Резултат

Първични изходни мерки

1. Mortality [through study completion, an average of 2 years]

All-cause mortality

2. Renal replacement therapy initiation [through study completion, an average of 2 years]

Start of hemodialysis or peritoneal dialysis

Вторични изходни мерки

1. Fragility [through study completion, an average of 2 years]

measured by Frailty scale

2. Sleep disorder based on polysomnography [through study completion, an average of 2 years]

polysomnography

3. Sleep disorder - somnolence [through study completion, an average of 2 years]

Epworth sleepiness scale

4. Sleep disorder - subjective quality of sleep [through study completion, an average of 2 years]

pittsburgh questionnaire

5. Sleep disorder - objective quality of sleep [through study completion, an average of 2 years]

actigraphy

6. Cognition [through study completion, an average of 2 years]

Montreal Cognitive Assessment

7. Nutrition [through study completion, an average of 2 years]

serum albumin

8. Nutrition [through study completion, an average of 2 years]

cuff circimference

9. Nutrition [through study completion, an average of 2 years]

body mass index

10. Nutrition [through study completion, an average of 2 years]

bioimpedance analysis

11. Mineral and bone markers [through study completion, an average of 2 years]

serum biomarkers

Присъединете се към нашата
страница във facebook

Най-пълната база данни за лечебни билки, подкрепена от науката

  • Работи на 55 езика
  • Билкови лекове, подкрепени от науката
  • Разпознаване на билки по изображение
  • Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
  • Прочетете научни публикации, свързани с вашето търсене
  • Търсете лечебни билки по техните ефекти
  • Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания

Google Play badgeApp Store badge